产品信息
抗原名称
SIRT1；SIRT2
商品描述
SRT 1720 is a selective activator of human SIRT1 (EC1.5: 0.16 μM) and is >230-fold less potent for SIRT2 and SIRT3.
分子量
469.56
纯度
≥98%
可溶性
10 mM in DMSO
外观
Yellow solid
In vitro(体外研究)
The maximum activation ratio of SRT1720 versus the closest sirtuin homologs, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration .
In vivo(体内研究)
SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces the hyperinsulinemia after 4 weeks, partially normalizing elevated insulin levels similar to rosiglitazone treatment. SRT 1720 treatment significantly reduces fasting blood glucose to near normal levels in Lepob/ob mice. SRT 1720 has the ability to protect against the negative effects of diet-induced obesity in mice and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development, attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice.
背景
别名
SRT-1720；SRT1720
分子式
C25H23N7OS
CAS号
925434-55-5
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
参考图片
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.iamyjet.com/article/14007.html